Cost-effectiveness of High-Dose Influenza Vaccination in the Netherlands: Updated Analysis Incorporating New Evidence

An updated cost-effectiveness analysis incorporating new evidence from over 85 million individuals confirms that high-dose inactivated influenza vaccination is highly cost-effective for adults aged 60 and older in the Netherlands, supporting its inclusion in the national immunization program.

The Gist

Imagine the flu vaccine as a shield against a storm. For decades, people over 60 have been given a "standard shield" (the standard-dose vaccine). But scientists recently discovered that a "heavy-duty shield" (the high-dose vaccine) is much stronger at keeping the storm out for older adults.

This paper asks a simple but crucial question: Is it worth the extra money to switch everyone over 60 to the heavy-duty shield?

Here is the breakdown using everyday analogies:

1. The New Evidence: A Bigger Picture

Previously, we only had a few small studies to judge the heavy-duty shield. But the researchers just finished a massive "mega-study." Imagine they didn't just look at one neighborhood; they looked at 85 million people across 14 different flu seasons. This gave them a crystal-clear view of how well the heavy-duty shield actually works in the real world, not just in a lab.

2. The Test Drive: Two Ways to Look at the Data

The researchers ran their numbers using two different maps:

• Map A (The Strict Lab Test): This only looked at the most controlled, scientific experiments.
• Map B (The Real-World Drive): This mixed the lab tests with what actually happens on the streets (real-world evidence).

Both maps showed the same story: The heavy-duty shield is better. It stops more people from getting sick (like the flu) and keeps more people out of the hospital (especially for heart and lung issues).

3. The Price Tag: Is It a Bargain?

In the world of health economics, there's a "price tag" for how much we are willing to pay to keep someone healthy for an extra year. In the Netherlands, that price tag is usually €20,000.

• The Result: The heavy-duty vaccine costs only €7,300 (or even €5,800 with real-world data) to save one year of healthy life.
• The Analogy: Think of it like buying a car. If you could buy a luxury car that saves you from accidents for only a fraction of the price of a standard sedan, you'd call it a "steal." That is exactly what this vaccine is. It is highly cost-effective.

4. The Impact: What Happens If We Switch?

If the Netherlands decides to switch to the heavy-duty vaccine for everyone over 60, the results would be like turning on a floodgate that stops water from overflowing:

• 7,200 fewer trips to the doctor's office.
• 6,300 fewer people ending up in the hospital for heart or lung trouble.
• 269 fewer deaths.

The Bottom Line

The researchers ran the numbers thousands of times (like rolling dice to check for luck) and found that there is a 99% chance this switch is a smart financial move.

In short: The heavy-duty flu vaccine is the "premium shield" that works better and costs less than we thought. It saves lives, keeps people out of hospitals, and saves the country money in the long run. The paper concludes that the Netherlands should definitely put this vaccine in the national plan for all seniors.

Technical Summary

Technical Summary: Cost-effectiveness of High-Dose Influenza Vaccination in the Netherlands

1. Problem Statement

Influenza poses a significant public health burden, particularly among adults aged 60 years and older, who are at higher risk for severe complications, hospitalization, and mortality. While standard-dose inactivated influenza vaccines (SD-IIV) are widely used, evidence suggests that high-dose inactivated influenza vaccines (HD-IIV) offer superior immunogenicity and effectiveness in this elderly demographic. However, the decision to implement HD-IIV in national immunization programs requires robust economic justification. The core problem addressed in this study is determining whether the incremental health benefits of HD-IIV over SD-IIV justify the additional costs within the specific context of the Netherlands, utilizing the most recent and comprehensive evidence available.

2. Methodology

The study employed a health economic modeling approach to update a previously developed model with a lifetime horizon and a societal perspective. The analysis focused on the Dutch population aged ≥60 years. Key methodological updates included:

• Data Integration: The model incorporated a recent meta-analysis encompassing over 85 million individuals across 14 influenza seasons to refine relative vaccine effectiveness (rVE) estimates.
• Effectiveness Scenarios: Two distinct evidence scenarios were modeled to test robustness:
  1. RCT Evidence Only: Based solely on Randomized Controlled Trials, showing an rVE of 24% for Influenza-like Illness (ILI) and 7% for cardiorespiratory hospitalizations.
  2. RCT + Real-World Evidence (RWE): A composite of RCTs and real-world observational data, showing an rVE of 15% for ILI and 8% for cardiorespiratory hospitalizations.
• Parameters: The model was updated with current demographic data, cost structures, hospitalization rates, and the aforementioned rVE parameters.
• Uncertainty Analysis: Probabilistic sensitivity analysis (PSA) was conducted to assess the robustness of the results against parameter uncertainty.

3. Key Contributions

• Evidence Synthesis: The study uniquely integrates a massive meta-analysis (85M+ individuals) into a cost-effectiveness model, bridging the gap between clinical trial data and real-world effectiveness.
• Scenario Comparison: By explicitly comparing an RCT-only scenario against an RCT+RWE scenario, the study provides a nuanced view of how different evidence sources impact economic outcomes.
• Policy Relevance: The analysis is tailored specifically to the Dutch healthcare system, providing actionable data for the national immunization program regarding the adoption of HD-IIV.

4. Results

The updated analysis yielded the following key findings:

• Cost-Effectiveness Ratios (ICERs):
  • Under the RCT-only scenario, the Incremental Cost-Effectiveness Ratio (ICER) was €7,300 per Quality-Adjusted Life Year (QALY).
  • Under the RCT+RWE scenario, the ICER was even more favorable at €5,800 per QALY.
• Health Impact (RCT Scenario): Implementing HD-IIV is projected to prevent:
  • 7,200 General Practitioner (GP) visits.
  • 6,300 cardiorespiratory hospitalizations.
  • 269 deaths.
• Probabilistic Sensitivity: The PSA demonstrated a >99% probability that HD-IIV is cost-effective at a standard willingness-to-pay threshold of €20,000 per QALY for both evidence scenarios.

5. Significance and Conclusion

The study concludes that High-Dose Influenza Vaccination is highly cost-effective for Dutch adults aged 60 and older, even when accounting for updated parameters and varying evidence sources. The ICERs are well below the commonly accepted Dutch threshold of €20,000–€50,000 per QALY.

The findings strongly support the implementation of HD-IIV into the national immunization programme. By preventing thousands of hospitalizations and hundreds of deaths, the switch from standard-dose to high-dose vaccines offers substantial health gains that outweigh the incremental costs, validating a shift in public health strategy for the elderly population in the Netherlands.